- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 14, Issue 4, Pages 203-220
Publisher
Springer Nature
Online
2016-11-02
DOI
10.1038/nrclinonc.2016.168
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients
- (2016) Timothy S. Fenske et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas
- (2016) L. C. Chong et al. BLOOD
- PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
- (2016) H. Miyoshi et al. BLOOD
- Follicular lymphoma: evolving therapeutic strategies
- (2016) B. S. Kahl et al. BLOOD
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base
- (2016) Adam J. Olszewski et al. CANCER
- Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
- (2016) Thomas Menter et al. HUMAN PATHOLOGY
- Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
- (2016) Ronald C. Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and Epigenetic Regulation of PD-1 Expression
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals
- (2016) Riddhima Banga et al. NATURE MEDICINE
- Study deciphers enigmatic mechanism of PD-L1 overexpression
- (2016) David Killock Nature Reviews Clinical Oncology
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma
- (2016) Wei Ju et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling
- (2015) Ji Yuan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- How I treat advanced classical Hodgkin lymphoma
- (2015) P. Johnson et al. BLOOD
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation
- (2015) C. Schmid et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation
- (2015) S R Pingali et al. BONE MARROW TRANSPLANTATION
- New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT
- (2015) X Chang et al. BONE MARROW TRANSPLANTATION
- Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
- (2015) Rita Nanda et al. CANCER RESEARCH
- Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
- (2015) Nobuhiko Nakamura et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group
- (2015) Dennis A. Eichenauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Structural genomic alterations in primary mediastinal large B-cell lymphoma
- (2015) David D. W. Twa et al. LEUKEMIA & LYMPHOMA
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
- (2015) Vijayakumar Velu et al. Retrovirology
- Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
- (2015) Michael T. Barrett et al. Oncotarget
- Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma
- (2015) Matthew A. Care et al. Genome Medicine
- Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
- (2014) Min Shi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis
- (2014) C. Chao et al. ANNALS OF ONCOLOGY
- Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
- (2014) Kieron Dunleavy et al. BLOOD
- Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
- (2014) David D. W. Twa et al. BLOOD
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
- (2014) Laurie H. Sehn et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
- (2014) Y. Hao et al. CLINICAL CANCER RESEARCH
- Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma
- (2014) J. P. Smeltzer et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes
- (2014) Naoko Okiyama et al. JOURNAL OF AUTOIMMUNITY
- Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
- (2014) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- B7H1/CD80 Interaction Augments PD-1–Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease
- (2014) Ruishu Deng et al. JOURNAL OF IMMUNOLOGY
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Diagnosis and management of lymphomas and other cancers in HIV-infected patients
- (2014) Antonino Carbone et al. Nature Reviews Clinical Oncology
- Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma
- (2014) Matthew J. Ahearne et al. VIRCHOWS ARCHIV
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
- (2013) J. H. Myklebust et al. BLOOD
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
- (2013) T. J. Kearl et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
- (2013) S Munir et al. LEUKEMIA
- Love the one you're with: the HIV, B cell and TFH cell triangle
- (2013) Shiv Pillai NATURE MEDICINE
- Inadequate T follicular cell help impairs B cell immunity during HIV infection
- (2013) Rafael A Cubas et al. NATURE MEDICINE
- Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
- (2013) Kieron Dunleavy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- Update on the treatment of HIV-associated hematologic malignancies
- (2013) R. F. Little et al. Hematology-American Society of Hematology Education Program
- Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
- (2012) R. Chen et al. BLOOD
- The role of B7 family molecules in hematologic malignancy
- (2012) P. Greaves et al. BLOOD
- How I treat HIV-associated lymphoma
- (2012) K. Dunleavy et al. BLOOD
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- (2011) Kanchan Kantekure et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Follicular Helper CD4 T Cells (TFH)
- (2011) Shane Crotty Annual Review of Immunology
- Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
- (2011) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The molecular pathogenesis of primary mediastinal large B-cell lymphoma
- (2011) C. Steidl et al. BLOOD
- Review of the cardiac long-term effects of therapy for Hodgkin lymphoma
- (2011) Andrea K. Ng BRITISH JOURNAL OF HAEMATOLOGY
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Follicular programmed death 1–positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma
- (2011) Bill G. Richendollar et al. HUMAN PATHOLOGY
- How I treat HIV-associated multicentric Castleman disease
- (2010) M. Bower BLOOD
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
- (2010) Marita Ziepert et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
- (2010) Kim L Good-Jacobson et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
- (2009) R. A. Wilcox et al. BLOOD
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
- (2009) Joaquim Carreras et al. JOURNAL OF CLINICAL ONCOLOGY
- Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
- (2009) Apostolia-Maria Tsimberidou et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
- (2008) Luc Xerri et al. HUMAN PATHOLOGY
- PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients
- (2008) T Kozako et al. LEUKEMIA
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now